1675201-83-8
中文名称
PD-1
英文名称
2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-
CAS
1675201-83-8
分子式
C29H33NO5
分子量
475.58
MOL 文件
1675201-83-8.mol
更新日期
2025/05/09 15:07:11
1675201-83-8 结构式
基本信息
中文别名
PD-L1 抑制剂1化合物PD-1/PD-L1 INHIBITOR 1
(S)-1-(2,6-二甲氧基-4-((2-甲基-[1,1'-联苯]-3-基)甲氧基)苄基)哌啶-2-甲酸
(2S)-1-[[2,6-二甲氧基-4-[(2-甲基[1,1'-联苯]-3-基)甲氧基]苯基]甲基]-2-哌啶羧酸
英文别名
T3655BMS-1
CS-2413
avelumab/PD-L1
PD-1PD-L1 inhibitor
PD1-PDL1 inhibitor 1
PD-1/PD-L1 inhibitor 1(C1)
BMS-1 (PD-1/PD-L1 inhibitor 1)
PD1-PDL1 inhibitor 1 (PD1-PDL1-IN1)
PD1/PDL1 INHIBITOR 1
PD 1/PD L1 INHIBITOR 1
所属类别
生物化工：激动剂抑制剂物理化学性质
沸点630.2±55.0 °C(Predicted)
密度1.182±0.06 g/cm3(Predicted)
储存条件-20°C
溶解度可溶于 DMSO（高达至少 25 mg/ml）或乙醇（高达 20 mg/ml）
酸度系数(pKa)2.34±0.20(Predicted)
形态固体
颜色白色
稳定性Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
PD-1价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-19991 | PD-1 BMS-1 | 1675201-83-8 | 1 mg | 496元 |
| 2025/02/08 | HY-19991 | PD-1 BMS-1 | 1675201-83-8 | 5mg | 1200元 |
| 2025/02/08 | HY-19991 | PD-1 BMS-1 | 1675201-83-8 | 10mM * 1mLin DMSO | 1256元 |
常见问题列表
生物活性
BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1)是一种PD-1/PD-L1相互作用的小分子化合物抑制剂，IC50为6 nM。靶点
| Target | Value |
|
PD-1/PD-L1 interaction
(Cell-free assay) | 0.006 μM |
体外研究
Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy.
Cell Cytotoxicity Assay
| Cell Line: | NK cells and HepG2 cells |
| Concentration: | 1 μM |
| Incubation Time: | 3 days |
| Result: | Disturbed the interaction between PD-1 and PD-L1. |
体内研究
BMS-1 (500 μg/mL; 100 μL; i.p.) significantly slows down tumor growth and prolongs the survival rates in BALB/c mice.
| Animal Model: | BALB/c mice |
| Dosage: | 500 μg/mL; 100 μL |
| Administration: | I.p. |
| Result: | Administration significantly slowed down tumor growth and prolonged the survival rates. |